Edition:
India

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

82.24USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$82.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
241,581
52-wk High
$135.59
52-wk Low
$51.11

Chart for

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -2.06
Market Cap(Mil.): $1,754.86
Shares Outstanding(Mil.): 25.10
Dividend: --
Yield (%): --

Financials

BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln

* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE

08 May 2018

BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million

* INTERCEPT PHARMACEUTICALS SAYS CEO MARK PRUZANSKI'S FY 2017 TOTAL COMPENSATION WAS $6.2 MILLION VERSUS $4.8 MILLION IN 2016 - SEC FILING Source text for Eikon: (http://bit.ly/2KlDqOX) Further company coverage:

28 Apr 2018

BRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors

* INTERCEPT PHARMACEUTICALS SAYS EFFECTIVE APRIL 24, CO'S BOARD INCREASED SIZE OF BOARD FROM NINE DIRECTORS TO TEN DIRECTORS - SEC FILING Source text: [https://bit.ly/2JsU4uo] Further company coverage:

27 Apr 2018

BRIEF-Intercept Pharmaceuticals Announces Pricing Of Upsized $250 Mln Public Offering And Concurrent Private Placement Of Common Stock

* INTERCEPT PHARMACEUTICALS ANNOUNCES PRICING OF UPSIZED $250 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT OF COMMON STOCK

05 Apr 2018

BRIEF-Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31

* EXPECTS NET SALES OF OCALIVA FOR QUARTER ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QUARTER ENDED DEC 31, 2017​ Source text (https://bit.ly/2uINGwG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

05 Apr 2018

BRIEF-Intercept Pharma Says U.S. Court Granted Defendants Motion & Dismissed With Prejudice Derivative Lawsuit Purportedly Brought On Behalf Of Company

* INTERCEPT PHARMA - U.S. COURT GRANTED DEFENDANTS MOTION & DISMISSED WITH PREJUDICE DERIVATIVE LAWSUIT PURPORTEDLY BROUGHT ON BEHALF OF COMPANY

27 Mar 2018

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

17 Feb 2018

BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43

* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

14 Feb 2018

BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva

* INTERCEPT ANNOUNCES UPDATED U.S. PRESCRIBING INFORMATION FOR OCALIVA® (OBETICHOLIC ACID) TO REINFORCE APPROPRIATE DOSING IN PBC PATIENTS WITH ADVANCED CIRRHOSIS

01 Feb 2018

BRIEF-Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018

* INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING Source text: (http://bit.ly/2CgH2Og) Further company coverage:

28 Dec 2017

Competitors

Earnings vs. Estimates